Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Canagliflozin

FDA-approved product (tablet, oral), marketed as Canagliflozin, Invokana.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Canagliflozin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Sodium-glucose co-transporter 2 (sglt2) inhibitors
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli27.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae21.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis45.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Canagliflozin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Canagliflozin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Pioglitazone and SGLT2 Inhibitors vs. DPP4 Inhibitors in Patients With Stroke

    NCT04419337 · start 2019-09-15

    Registered record
    Registry ID
    NCT04419337
    Conditions
    Diabetes Mellitus; Stroke
    Interventions
    Metformin plus Pioglitazone plus an SGLT2 inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2019-09-15
    Completion
    2024-01-31
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus; Stroke
    InterventionMetformin plus Pioglitazone plus an SGLT2 inhibitor
    PhasePhase 2
    Registry statusUnknown

  • Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus

    NCT04014192 · start 2019-09-01

    Registered record
    Registry ID
    NCT04014192
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Dapagliflozin; Empagliflozin; Canagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2019-09-01
    Completion
    2020-07-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionDapagliflozin; Empagliflozin; Canagliflozin
    PhasePhase 4
    Registry statusUnknown

  • Metformin And Cardiovascular Effectiveness vs SGLT2 (MACES)

    NCT03627039 · start 2018-09-01

    Registered record
    Registry ID
    NCT03627039
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    SGLT2; Metformin
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-09-01
    Completion
    2020-08-01
    Enrolment
    20,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionSGLT2; Metformin
    PhaseNot recorded
    Registry statusUnknown

  • Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy

    NCT03436693 · start 2018-02-15

    Registered record
    Registry ID
    NCT03436693
    Conditions
    Diabetic Nephropathy
    Interventions
    Canagliflozin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2018-02-15
    Completion
    2021-01-21
    Enrolment
    308

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetic Nephropathy
    InterventionCanagliflozin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Role of Canagliflozin on CD34+ Cells in Patients With Type 2 Diabetes

    NCT02964585 · start 2016-11

    Registered record
    Registry ID
    NCT02964585
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Canagliflozin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-11
    Completion
    2020-09
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionCanagliflozin; Placebo
    PhasePhase 4
    Registry statusCompleted

  • A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

    NCT02851212 · start 2016-08

    Registered record
    Registry ID
    NCT02851212
    Conditions
    Healthy
    Interventions
    Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]; Canagliflozin; Canagliflozin; Metformin Extended Release (XR)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-08
    Completion
    2016-10
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCanagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]; Canagliflozin; Canagliflozin; Metformin Extended Release (XR)
    PhasePhase 1
    Registry statusCompleted

  • Canagliflozin (Invokana™) vs. Standard Dual Therapy Regimen for T2DM During Ramadan

    NCT02694263 · start 2016-07

    Registered record
    Registry ID
    NCT02694263
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    Canagliflozin; Repaglinide; Pioglitazone; Gliclazide; Glimepiride
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-07
    Completion
    2018-09-13
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionCanagliflozin; Repaglinide; Pioglitazone; Gliclazide +1 more
    PhasePhase 4
    Registry statusCompleted

  • The Effect of add-on Canagliflozin in Patients With Type 2 Diabetes Treated With U-500 Insulin

    NCT02597309 · start 2015-11

    Registered record
    Registry ID
    NCT02597309
    Conditions
    Diabetes, Obesity
    Interventions
    Canagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2015-11
    Completion
    2017-07
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes, Obesity
    InterventionCanagliflozin
    PhasePhase 4
    Registry statusWithdrawn

  • Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents

    NCT02636192 · start 2015-07-31

    Registered record
    Registry ID
    NCT02636192
    Conditions
    Diabetes Mellitus, Type 2
    Interventions
    No Intervention
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2015-07-31
    Completion
    2017-04-07
    Enrolment
    200,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes Mellitus, Type 2
    InterventionNo Intervention
    PhaseNot recorded
    Registry statusCompleted

  • Long-Term Safety Study of Canagliflozin (TA-7284) in Combination With Insulin in Patients With Type 2 Diabetes Mellitus

    NCT02622113 · start 2014-12

    Registered record
    Registry ID
    NCT02622113
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Canagliflozin (TA-7284); Insulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-12
    Completion
    2016-04
    Enrolment
    139

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionCanagliflozin (TA-7284); Insulin
    PhasePhase 4
    Registry statusCompleted

  • Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients

    NCT02324842 · start 2014-11

    Registered record
    Registry ID
    NCT02324842
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Canagliflozin; Liraglutide
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2014-11
    Completion
    2019-03-31
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionCanagliflozin; Liraglutide
    PhaseNot applicable
    Registry statusCompleted

  • Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants

    NCT02220218 · start 2014-08

    Registered record
    Registry ID
    NCT02220218
    Conditions
    Healthy
    Interventions
    Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC); Canagliflozin; Metformin IR
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-08
    Completion
    2014-10
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCanagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC); Canagliflozin; Metformin IR
    PhasePhase 1
    Registry statusCompleted

  • Long-Term Safety Study of MT-2412 in Japanese Patients With Type 2 Diabetes

    NCT02220907 · start 2014-08

    Registered record
    Registry ID
    NCT02220907
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    Teneligliptin/Canagliflozin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-08
    Completion
    2016-02
    Enrolment
    153

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionTeneligliptin/Canagliflozin
    PhasePhase 3
    Registry statusCompleted

  • Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

    NCT02221180 · start 2014-08

    Registered record
    Registry ID
    NCT02221180
    Conditions
    Bioequivalence
    Interventions
    Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]; Canagliflozin; Metformin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-08
    Completion
    2014-11
    Enrolment
    2

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionCanagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]; Canagliflozin; Metformin
    PhasePhase 1
    Registry statusCompleted

  • A 6-Week Study To Determine The Safety And Effect Of An Investigational Drug Given With Canagliflozin In Adults With Type 2 Diabetes Mellitus Taking Metformin

    NCT02053116 · start 2014-03

    Registered record
    Registry ID
    NCT02053116
    Conditions
    Type 2 Diabetes Mellitus
    Interventions
    PF-05175157; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2014-03
    Completion
    2014-04
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes Mellitus
    InterventionPF-05175157; Placebo
    PhasePhase 2
    Registry statusTerminated